A recent selloff of Neurocrine Biosciences stock feels unwarranted and may have created a contrarian buy opportunity. Learn ...

Do not take INGREZZA or INGREZZA SPRINKLE if you: are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE. INGREZZA or INGREZZA SPRINKLE can cause serious side ...

Ingrezza (valbenazine) is a brand-name oral capsule prescribed for tardive dyskinesia and Huntington’s chorea. The cost of the drug with and without insurance can depend on several factors.

Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine).

open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily ingrezza – valbenazine – capsules. This analysis was presented at ...

(RTTNews) - Neurocrine Biosciences Inc. (NBIX), Thursday unveiled new data at the 2025 Psychiatry Update Conference in Chicago, highlighting the long-term efficacy of INGREZZA or valbenazine in ...

open-label KINECT ® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily INGREZZA ® (valbenazine) capsules. This analysis was presented at ...

TD is estimated to affect at least 800,000 adults in the U.S. About INGREZZA ® (valbenazine) Capsules and INGREZZA ® SPRINKLE (valbenazine) Capsules INGREZZA is a selective vesicular ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...